SAB Biotherapeutics, Inc. (SABSW) stock

SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30

$0.01+0.00 (+33.33%)

Close on Oct 20, 2026Market cap $304.80MP/E –Yield –

SAB Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

SAB Biotherapeutics's pe ratio was 13.4× on Apr 30, 2026, against 23.6× a year earlier.

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	13.4×	+3.9
2025	Dec 31, 2025	9.5×	−4.4
2022	Jan 31, 2022	13.9×	−4.8
2021	Dec 31, 2021	18.6×	–

Parsed from the XBRL in SAB Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5.67 reverse split on Mar 29, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SABSW.

Revenue growth-100.0% · median 15.6%

Advertisement
300 × 250